Pregen Shenzhen Biotechnology

Pregen (Shenzhen) Biotechnology is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative antibody-based therapeutics for oncology and autoimmune diseases. The company utilizes its proprietary P-Body platform to engineer next-generation biologics, including bispecific antibodies and antibody-drug conjugates (ADCs). Their lead programs target high-value antigens such as Claudin 18.2 and PD-1, aiming to address unmet medical needs in gastrointestinal and lung cancers. Pregen maintains a robust R&D infrastructure in Shenzhen, China, integrating drug discovery with translational medicine. The company is actively advancing multiple candidates through early-phase clinical trials while expanding its pipeline through strategic collaborations.